Bristol Myers Squibb completes acquisition of Karuna Therapeutics
MLex Summary: Bristol Myers Squibb said that it has successfully completed its acquisition of Karuna Therapeutics. With the acquisition’s closing, Karuna shares have ceased trading on the Nasdaq Global Select Market...To view the full article, register now.
Already a subscriber? Click here to view full article